QCM Cayman’s BioNTech BNTX Stock Holding History

QCM Cayman’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,222	Closed	-$274K	–	118
2021 Q2	$274K	Buy	+1,222	New	+$230K	0.71%	53

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

QCM Cayman's BNTX Position: Q3 2021 in Review

QCM Cayman sold out of BioNTech (BNTX) in Q3 2021, closing a stake of 1,222 shares — an estimated $274K sold.

QCM Cayman first reported a position in BNTX in Q2 2021 and held it in 1 quarter. The position peaked at $274K in Q2 2021. 335 funds tracked by Wall St. Rank hold BNTX as of Q3 2021.

QCM Cayman reported no remaining BioNTech position as of Q3 2021 after selling out during the quarter.
QCM Cayman sold 1,222 BioNTech shares in Q3 2021, an estimated $274K.
QCM Cayman first reported a position in BioNTech in Q2 2021 and held it in 1 quarter.
QCM Cayman's BioNTech position peaked at $274K in Q2 2021.
335 funds tracked by Wall St. Rank held BioNTech as of Q3 2021.

Based on QCM Cayman's 13F filing for Q3 2021, filed 1 Nov 2021.